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The etiology ofalopecia areata (AA), a putative autoimmune disease character-
ized by sudden hair loss, has remained obscure. It is not understood, how the
characteristic inflammatory infiltrate that selectively attacks anagen hair folli-
cles in AA is generated. We hypothesize that this reflects an unexplored form
of autoimmunity, a cytotoxic T cell attack on rhythmically synthesized
autoantigens normally sequestered by a lack or very low level of MHC class I
(MHC I)-expression, and suggest the following mechanism of AA pathogene-
sis:
Microtrauma, neurogenic inflammation, or microbial antigens cause a localized
breakdown of MHC I-"negativity" in the proximal anagen hair bulb via proin-
flammatory cytokines. This exposes autoantigens derived from melanogenesis-
related proteins (MRP-DP), which are only generated during anagen, and trig-
gers two successive waves of autoimmune responses: CD8* cytotoxic T cells
initiate AA after recognizing MRP-DP abnormally presented by MHC I
molecules on hair matrix melanocytes and/or keratinocytes; a secondary attack,
carried by CD4+ T cells and antigen presenting cells, is then mounted against
MHC class II - presented additional autoantigens exposed by damaged
melanocytes and keratinocytes. The latter causes mostof the follicular damage,
and extrafollicular disease, and depends greatly on the immunogenetic back-
ground of affected individuals. This unifying hypothesis explains the clinical
heterogeneity and all salient features of AA, and argues that only the unlikely
coincidence of multiple predisposing events triggers AA. The suppression of
MHC I- expression and synthesis of MRP in the hair bulb, and the "toleriza-
tion" of MRP-DP autoreactive CD8+ T cells may be promising strategies for
treating AA.
The etiology of AAd, an enigmatic form of rapidly developing hair loss with often
devastating psychological effects, has long been the subject of animated debate. While
early in AA research roles for the nervous system and for infectious agents in the patho-
genesis ofAA werepostulated ("trophoneurotic theory", theory ofbacterial "foci"), today
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most authors tend to classify AA as an autoimmune disease [1-3]. Yet, this is only sup-
ported by circumstantial evidence, and no etiologic concept is generally accepted. A
deeper understanding of the etiology of AA is not only important for evident clinical
reasons, but is ofwiderbiological interest, since this disease may reflecta still uncharted,
general principle of autoaggression relevant to other ill-understood putative "autoim-
mune" diseases.
The characteristic T cell-dominated inflammatory infiltrate attacking the hairfollicle,
the association ofAA with otherautoaggressive diseases, various autoantibodies and oth-
er abnormalities of humoral and cellular immune parameters, as well as evidence for
immunogenetic influences, suggest an autoimmune response as the underlying patho-
genetic principle in AA. The significance of these findings, however, remains uncertain
and controversial [1-3]. Neither the presence of autoantibodies nor linkage with certain
HLA alleles alone can be accepted as firm evidence for an autoimmune disease [4, 5].
Autoantibodies to hair follicle-associated antigens occur in normal individuals [6], and
many autoantibodies may serve physiological functions [5, 7]. No specific follicular
autoantigen has been identified as responsible for triggering AA, and neither passive
transfer ofan AA-like disease state by Tcells or serum, norcell-mediated induction ofan
experimental analogue of AA have been demonstrated [8, cf. 4]. Initial hopes that the
abnormal expression of MHC class II molecules by lesional hair bulb KC may explain
the initiation ofan autoimmune attack [9] waned when it was shown thatthe inflammato-
ry infiltrate appears on the scene before HLA-DR expression ofhair bulb KC is detected
[10] (secondary, aberrant MHC class II expression is seen in many autoimmune diseases
[5]).
The search for a convincing etiologic theory is complicated by uncertainty on
whether all cases of AA represent manifestations ofthe same disease [11]. Even in cases
with similar presenting signs one sees considerable variation in the associated diseases,
immunological and endocrinological laboratory findings, family history, history ofatopy,
HLA-association, prognosis, course, and response to therapy [1, 2, 11]. As long as one
adheres to the view of AA as a single disease entity, in our view, any credible theory
should integrate the following salientfeatures ofAA.
CLINICAL CHARACTERISTICS OF AA [1,2]
AA is characterized by the sudden onset of predominantly non-scarring, reversible
hair loss with striking absence of visible signs of skin inflammation. Though dramatic
forms ofrapid disease progression leading to the loss ofall body hairdooccur, the major-
ity ofpatients suffers hair loss in peculiarly circumscribed skin areas. Heavily pigmented
scalp and beard hair follicles, which display the highest percentage offollicles in anagen
(i.e., the growth phase of the hair cycle), are affected most often. Hair loss is often
accompanied by nail dystrophy, and AA patients have an increased incidence of abnor-
mal thyroid function and other autoimmune diseases, including vitiligo, and a higher
prevalence of other pigmentary defects (e.g., Vogt-Koyanagi-Harada syndrome, ocular
depigmentation in the retinal epithelium). Remarkably, white or greying hair follicles are
commonly spared in AA, while regrowing hair shafts usually are white before they
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follicles so that only pre-existing grey or white hair is left behind, may underlie the
mysterious phenomenon of "overnightgreying."
In a minority of cases, AA disease onset coincides with severe emotional stress,
surgery, dental manipulations, head trauma, bacteremia and/or the presence of so-called
bacterial "foci." The course of AA is entirely unpredictable, with a high rate of sponta-
neous remission, and a worse prognosis in patients with rapid progression, nuchal hair
loss, and onset before puberty. Hints at genetic factors arise from the observation that a
worse prognosis is also seen in patients with a positive family history for AA and/or a
personal history ofatopy, and that the incidence ofAA appears to be highest among dark
black-haired Japanese, and rather low in fair-haired Scandinavians (reliable epidemiolog-
ical data are wanting, however). Though a wide spectrum of immunomodulatory treat-
ment strategies all may induce hair regrowth, the response to therapy is often unsatisfac-
tory, andrelapses afterdiscontinuation oftherapy are very common.
HISTOPATHOLOGY OF AA [1,2, 13]
The earliestrecognized histological sign ofAA areperi- and intrafollicular as well as
perivascular inflammatory infiltrates composed primarily ofactivated T lymphocytes and
macrophages. Typically, these cells assemble in a "bee-swarm"-like fashion around the
proximal hair bulb of affected follicles, and some inflammatory cells invade the hair
matrix. Without this infiltrate, there is no AA, and only melanogenically active anagen
follicles (anagen HI-VI) come under attack. It has not been clarified definitively which
anagen substage is assaulted: an arrest of follicles in anagen III-IV is well-documented
[12, 13], but also anagen VI may be attacked [14]. In acute AA lesions, intrabulbar
inflammatory cells can be detected in close proximity to hair matrix MC [3], and KC of
the precortical hairbulb matrix show ultrastructural signs ofcell damage [15]. This cellu-
lar attack on the follicle terminates anagen prematurely and precipitates the follicle into
catagen, often with signs offollicle dystrophy; these include abnormal pigmentation and
matrix degeneration [16], but, with rare exception, there is no follicle destruction.
Consequently, lesional skin displays an abnormally high percentage of catagen and telo-
gen follicles [13]. Signs offollicular KC and MC degeneration, including more apoptosis
ofproximal hair bulb KC than one normally finds during follicle regression (catagen) are
seen in acute AA [16, 17]. Other structural abnormalities of AA follicles have been
described in the dermal papilla and in the epithelial-mesenchymaljunction zone between
hairbulb andpapilla [13, 15, 18, 19].
IMMUNOLOGY OF AA
The inflammatory infiltrate in the acute phaseofAA consists ofboth activated CD4+
and ofCD8+ T cells as well as ofmacrophages and someLangerhans cells,possibly with
arelative predominance ofhelper (CD4+) overcytotoxic (CD8+) T cells [1-3]. The exact
order of appearance of these various mononucleas cell populations has not been estab-
lished, mainly because the pathogenic process is already faradvanced at the time ofvisi-
ble hair loss, i.e., when most biopsies are taken, and biopsies from the perimeter of an
acute lesion orfrom clinically uninvolved skin may notaccurately reflect the very earliest
stage of AA pathogenesis. However, CD8+ T cells can be seen to invade the proximal
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Strong MHC class I (MHC I) immunoreactivity is found in the proximal hairbulb of
AA follicles, which is in striking contrast to the normal MHC I-"negativity" in this region
[1-3, 10, 20-22]. In addition, an "ectopic" expression of MHC class II-molecules (e.g.,
HLA-DR) by hairbulb KC and increased numbersofMHC-class II+Langerhanscells are
found in many lesional hair bulbs [1-3, 15, 20, 22]. Normal proximal hair bulbs are
MHC class 11-negative, and Langerhans cells may be absent from the normal proximal
anagen hair follicle [1, 21, 22]. Early lesional AA follicles also display aberrant expres-
sion ofadhesion molecules known to direct hematopoietic cell extravasation and migra-
tion, while the epithelium of normal skin and hair follicles seems devoid of ICAM-1
immunoreactivity, theepithelial bulb ofAA follicles is strongly ICAM-1+ [cf. 23].
A large number of, at times, contradictory abnormalities of humoral and/or cell-
mediated immunity has been described in AA patients, butthepathogenic significance of
these findings remains controversial [1-3]. One fairly consistant finding is a higher inci-
dence of autoantibodies to thyroid microsomal and gastric parietal cell antigens in AA
than in controls [1, 2]. Recently, an enrichment of "autoreactive" T lymphocytes with
undefmed antigen-specificity in lesional AA scalp skin has been reported [24]. The asso-
ciation ofAA with HLA-haplotypes is still uncertain. Forexample, increased frequencies
ofthe MHC I alleles HLA-B8, 9, 12, 18 havebeen reported in some, butnotall AA pop-
ulations [cf. 25, 26]. Among the MHC class II-associations suggested for AA [1, 2], a
linkage with HLA-DR4 appears well-documented [25], while HLA-DRw52a may confer
relative protection from AA [26].
Among these features ofAA, the exclusive attack on melanogenically active anagen
follicles, the distinct pigmentation-phenomena listed above, and the association with
vitiligo all point to the follicular MC as a possibly important etiologic factor [cf. 3,
27-29]. In this context, some aspects of normal hair follicle biology must be kept in
mind:
a) MC enjoy some form of protection from immune recognition in the proximal
anagen hair follicle; in homografts ofguinea pig epidermis from black skin transplanted
to white skin beds ofan incompatible recipient strain, donor MC migrate into the recipi-
ent hair bulbs and, in contrast to epidermal MCs, survive there for an extended period of
time [cf. 30].
b) The MHC expression pattern in anagen hair follicles is highly unusual and may
explain a); in hair follicles of humans, rats and mice, MHC I expression in the proximal
hair bulb of anagen, but not telogen (= resting) follicles normally is either absent or
below detectablility by immunohistology [21, 31, 32]; this "lack" of classical MHC I
expression may be comparable to the situation in the fetotrophoblast [31, 32], where the
lack of HLA-A and HLA-B expression is utilized to prevent a maternal cytotoxic T cell
attack on paternal antigens generatedby the fetal "graft" [33].
c) Melanogenesis and melanosome transferral to cortical human hair bulb KC are
strictly coupled to the anagen stage of the hair cycle, are initiated during anagen III-IV,
and cease at the end ofanagen VI [28, 34, 35].
On this background, we argue that it will prove most incisive to clarify why only
melanogenically active anagen follicles are attacked, and why the normal anagen hair fol-
licle displays its peculiar pattern ofMHC I-expression, as well as to intensify the search
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research into this direction, we propose this hypothetical chain of events to result in the
development ofAA:
HYPOTHESIS
An anagen follicle becomes susceptible to an autoimmune attack only if the unique
repression ofMHC I-expression in its proximal bulb matrix fails as a resultofproinflam-
matory cytokines like INF-y, TNF-a and IL-1. These are released in response to rather
non-specific stimuli, like localized microtrauma, neurogenic inflammation, infectious
agents, or microbial superantigens. In some individuals, this abnormal MHC expression
exposes immunogenic peptides derived from melanogenesis-related proteins (MRP-DP)
via MHC I-molecules to the skin immune system. These peptides are only generated dur-
ing anagen-associated melanogenesis. If an individual has CD8+ T cells that recognize
MHC I-presented MRP-DP and receive a co-stimulatory signal, two successive waves of
immune responses are mounted.
The firstone actually triggers AA and is driven by autoreactive CD8+ Tcells launch-
ing a cytotoxic attack on hair matrix MC and/or KC presenting MRP-DP. The cytokines
and additional autoantigens released during this initial attack, and the abnormal expres-
sion of adhesion molecules induced thereby, subsequently attract a secondary immune
response, which involves CD4+ T cells, Langerhans cells, and macrophages. This sec-
ondary assault causes most of the follicular damage but varies greatly between affected
individuals, depending on their immunogenetic background, on the spectrum ofaddition-
ally exposed autoantigens, and on the nature oftheperturbation ofthe local cytokine net-
work. Damage to the dermal papilla, and induction ofabnormal KC apoptosis are thekey
factors in determining folliculardamage andrecovery.
Dependent on the level ofdamage, premature catagen induction and a reversible fol-
licle dystrophy ensue with the clinical result of hair shaft shedding. Autoantibodies and
autoreactive T cell clones generated during the secondary immune response perpetuate
the attack on the follicle, which is now also directed against MHC class II-dependent
autoantigens presented by ectopic MHC class II expression on hair matrix KC and/or by
the locally accumulated antigen presenting cells. These secondary autoantibodies and
autoreactive T cells account for the involvement ofextrafollicular cells with the same or
cross-reacting antigens (e.g., epidermal MC, nail matrix, thyroid gland). Regrowth of
depigmented hair shafts reflects both the damage inflicted on follicular MC and a protec-
tiveblockade ofMRPgeneration, which decreases the likelihood ofdiseaseperpetuation.
DISCUSSION
We propose that AA reflects a previously unexplored form ofautoimmunity: a cyto-
toxic T cell attack on rhythmically synthesized, normally sequestered autoantigens.
According to our hypothesis, the initiation ofAA is not based on an inherentabnormality
of hair follicle KC or MC functions, but results from the rare coincidence of several
events predisposing to disease development a cytokine-induced breakdown of MHC I-
"negativity" of the anagen hair bulb, the exposure of MRP-DP by MHC I, and the pres-
ence ofautoreactive CD8+ T cells that recognize MRP-DP and display cytotoxic activity.
In other words, different proinflammatory stimuli and pre-existing factors (e.g., presence
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increase the likelihood of developing AA, and then to coalesce into a cytotoxic T cell
attack that triggers AA.
Once launched, this attack on the follicle is portrayed tobe fueledandperpetuatedby
a cascade of secondary immune responses and proinflammatory cytokine-network alter-
ations. Most follicle damage and most of the immunological abnormalities seen in AA
patients are attributed to this set of secondary immune responses (e.g., autoantibodies,
CD4+ T cell-dominated infiltrate, ectopic MHC class II-expression, intrabulbar
Langerhans cells, abnormal adhesion molecule expression). These are thought to display
substantial inter-individual variations, depending on the immunogenetic background
(e.g., HLA-DR4), the response to additionally released orpresented autoantigens, and on
the local damage inflicted by the abnormal peri- and intrafollicular cytokine milieu. This
explains the heterogeneity ofAA cases, the strictassociation ofAA with melanogenically
active anagen folliclesandall othersalient featuresofAAoutlined above.
This hypothesis integrates previous suggestions that MC play a role in AA pathogen-
esis [3, 16,28, 29], and is in line with the concept thathaircycling and the severity ofthe
inflammatory damage to the hair follicle, particularly to the dermal papilla, play critical
roles in the pathogenesis ofAA [13, 18]. Our scenario works without having to postulate
an obscure inherent functional defect ofKC or MC [36], or abnormal adhesion molecule
expression [23], while itassigns adhesion molecules andchemotactic cytokines an impor-
tant role in the secondary autoimmune response [cf. 23, 36]. It extends upon the proposi-
tions that the intrabulbar changes in MHC expression seen in acute AA lesions facilitate
or even are responsible for induction of an immune response against unidentified
autoantigens [3] and that the follicular MHC I-"negativity" under physiological circum-
stances serves to prevent an immune response againstpotentially harmful antigens gener-
atedby melanogenically active MC [32].
The predominance of CD4+ T cells and MHC class II-restricted antigen presenting
cells in the inflammatory infiltrate has generally been interpreted as pointing to an MHC
class Il-dependent antigen as autoimmune target in AA. Yet, it remains unproven that
CD4+ Tcells appear on the scene before any CD8+ Tcells arrive, so the predominance of
CD4+ and APC cells could be a secondary event. The occurrence ofAA in AIDS patients
[37], who suffer from relative CD4+ T cell depletion, questions the relevance ofan MHC
class II-dependent initiating event. Recently, it was reported that experimental systemic
lupus erythematosus cannot be induced in an established murine model if test mice lack
MHC I molecules [38]. Since the incidence of lupus is increased in patients with AA [2,
39] this further encourages one to systematically explore the role of MHC I-presented
autoantigen(s) in AA.
Several aspects of the primary autoimmune response outlined here need to be
clarified:
How is MHC I-expression induced? What are the characteristics and determinants of
autoreactive T cell -, MHC I- and MRP-DP interactions? Why are there any autoreactive
CD8+ T cells at all, and what is the co-stimulatory signal required for cytotoxicity?
Which MRP are candidates for providing antigenic MRP-DP? And why are epidermal
MC only exceptionally affected in AA, leading to vitiligo, ifjoint MHC I expression and
melanogenesis predispose to an autoimmune attack on MC?Paus etal.: Alopecia areata: autoimmunity againstmelanogenesis-relatedproteins? S47
MHC I-EXPRESSION
Two mechanisms operating side by side could be responsible for abnormal MHC I
expression in the anagen hair bulb: stimulation by locally released cytokines known to
induce or enhance MHC I-expression, or failure to maintain suppression of MHC I-
expression. IFN-y and TNF-a, for example, stimulate MHC I expression [40], notably
also in organ-cultured human hair follicles [20]. Local microtrauma, or the stress-induced
release of substance P from the elaborate perifollicular nerve plexus with the conse-
quence of localized neurogenic inflammation [cf. 41-43], could create such a cytokine
milieu. MHC I expression as a consequence ofneurogenic inflammation in a limited skin
area corresponding to the distribution of selected cutaneous sensory nerves would nicely
explain why some patients appear to suffer their first attack of AA subsequent to emo-
tional orphysical trauma [2,44], and why the lesionsare usually so well-circumscribed.
Individuals, and distinct territories of hairy skin in a given individual, may differ in
the constitutive MHC I-repression ofanagen hair bulbs. This would account for varying,
genetically determined risk levels for developing AA in a specific location and for the
preference of AA for some cutaneous territories (e.g., nuchal skin). Likewise, microbial
antigens (e.g., streptococcal superantigens) released from infectious foci or during
bacteremia or viremia could indirectly account for a higher-than-normal level of MHC I
expression via the associated immune responses with enhanced, but localized IFN-y and
TNF-a secretion [cf. 7, 45, 46]. In a small minority of AA patients, where the clinical
history suggests involvement of an infectious agent/antigen in triggering the disease,
microbial superantigens may also act as MHC-nonrestricted polyclonal activators of
CD8+ T cells [cf. 7,45,46].
Since almost all nucleated somatic cells express MHC I constitutively, its "lack" of
expression likely is the resultofactive MHC I suppression. One candidate class I-repres-
sor is a-MSH, which suppresses epithelial cell MHC I expression in vitro [47]. This neu-
ropeptide is found in skin where it may even be generated locally [48]. Considering that
the proinflammatory cytokine IL-1 is a potent functional antagonist of a-MSH [48],
minor local inflammatory perturbations could easily disinhibit MHC I expression via the
IL-i-mediated antagonism of a-MSH. Accepting that enhanced IL-1 secretion is an
almost universal response to any kind of traumatic or inflammatory stimulus in the skin
[49, 50], the delicate milieuofregulatory factors maintaining relative MHC I-"negativity"
in the proximal hair bulb may easily be disturbed: MHC I-expression could become
upregulated almost explosively when both IL-I and IFN-yarepresent.
Cytokines releasedduring the initial cytotoxic attack may facilitate rapiddiseasepro-
gression by stimulating MHC I-expression in previously uninvolved neighboring follicles
ready to switch from early to mid anagen. This centrifugal propagation ofcytokine-medi-
ated, abnormal MHC I-expression would be limited by cytokine diffusion and inactiva-
tion, and would further explain the development of well-circumscribed AA lesions. Yet,
the rather non-specific pro-inflammatory events depicted above must be fairly frequent
events, and the vast majority of our scalp hair follicles are in anagen, thus generating
MRP. Why then does AA occur in less than 0.1 % ofindividuals [1], and not each time a
follicle switches on melanogenesis during anagen while its level ofMHC I expression is
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CD8+/ MHC /MRP-DPINTERACTIONS
We propose that AA is relatively rare due to a very low statistical chance ofa cyto-
toxic T cell attack on MRP-DP-presenting MC or KC. MRP-DP-reactive CD8+ T cell
clones must have escaped clonal elimination and induction ofanergy [5, 7,45]; they must
getinto directcontactwith an MRP-DPpresenting cell in the hair matrix, and - according
to current dogma - must receive a co-stimulatory signal necessary to induce cytotoxic
activity [7, 45, 51, 53]. Also, intracellular MHC I-molecules must fold properly around
MRP-DP to present them on thecell surface [7, 45, 51, 52]. The normal lack or low level
of MHC I-expression may serve to dramatically reduce the chance that such a fit is ever
made and that the few MHC molecules possibly expressed ever meet an autoreactive
T cell. Finally, only individuals expressing certain MHC I haplotypes may be at risk of
making an intracellular MHC/MRP-DP fit required for surface expression of the MHC-
peptide complex [7,45, 51, 52].
How doCD8+ Tcells getinto the hairbulb? Since the follicle isendowed with arich
perifollicular and intrapapillary vasculature, T cell trafficking between the hair matrix
and the dermal papilla is a reasonable possibility (reminder: the presence of intraepider-
mal T cells and of dermo-epidermal T cell trfficking [50] had long escaped notice). T
cells probably enter the hair bulb matrix rather infrequently, since immunohistology of
normal human anagen hair follicles does not usually reveal T cells in the matrix region.
However, the cytokines proposed to enhance MHC I-expression also are potent inducers
of adhesion molecules and could thus guide increased T cell numbers into the matrix
(e.g., both IFN-y and TNF-a stimulate the expression of ICAM-1 on KC and MC; [23,
49, 50]. Thus, stronger proinflammatory and MHC I-stimulating local perturbations
would greatly increase the chances for intrabulbar contact between MRP-DP and autore-
active Tcells.
AUTOREACTIVE, CYTOTOXIC CD8+ T CELLS
Since follicular melanogenesis commences already in utero, one would expect that
MRP-DP autoreactive thymocytes are eliminated during thymic maturation or are ren-
dered "anergic" after having come into contactwith MRP-DPas mature Tcells, assuming
these peptides are encountered without the required co-stimulatory signal [cf. 5, 7, 51,
53]. However, melanogenically active follicular MC may be shielded from contact with
the surrounding mesenchyme by a dense, glycosaminoglycan-rich extracellular matrix
that may obstruct [31], though not prevent, immune interactions. Thus, it is conceivable
that normallyfollicular MRP-DP are never presented to thymocytes or T cells and that,
therefore, circulating MRP-DP autoreactive CD8+ T cells do exist. Whether or not this is
the case may again be influenced by immunogenetic factors, namely by the expression
and activity of so-called immune response and immune suppression genes [cf. 5, 7, 45]
(cf. apparent AA-protective role ofHLA-Dw52a [26]). Whenever autoreactive T cells do
exist, under normal circumstances, the absence or very low level ofMHC I-expression in
the hair matrix would prevent MRP-DP recognition by the occasional T cell tafficking
through the matrix.
Once MHC I-expression has been stimulated, however, and additional T cells have
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cytokines responsible for this could also contribute signals promoting a cytotoxic attack
on MRP-DP expressing cells, now recognized for the first time by autoreactive T cells
(e.g., upregulation of target cell adhesion molecules; synergism of IL-1 and TNF-a with
IL-2 driven CD8+ T cell proliferation; enhancement of CTL formation by IFN-y).
Simultaneously present CD4+ T cells may provide co-stimulatory signals (e.g., IL-2) for
autoreactive CD8+ T cells, ifthe MRP-DP expressing cell does not produce such signals
like B7 expression [45, 51, 53]. Note that even human KC can be stimulated to express a
B7-like molecule in vitro [74]. Again, there is a chance to escape AA, ifMHC-presented
MRP-DP are not recognized as "foreign", or because no sufficient co-stimulation is
offered, thus inducing Tcell anergy [cf. 7, 51, 53].
MRP-DPAS AUTOANTIGENS
As outlined, the elusive follicular autoantigens in AA are probably generated only
during anagen, and may arise from melanogenically active MC [3, 28, 29].Though multi-
ple plasma membrane and extramelanosomal cytoplasmic melanocyte proteins, theoreti-
cally, could serve as donors for autoantigenic peptides, it is more reasonable to assume
that the donor proteins are melanocyte-specific. This designates melanosomal antigens
and other MRP transported into melanosomes likely candidates (e.g., tyrosinase,
DOPAchrome tautomerase [TRP-2], b-locus protein [TRP-1] and Pmel 17, addressed
together as MRP [54, 55] since they are considered to be the only melanocyte-specific
proteins [72]. In addition, melanosomes and MRP are synthesized in hair follicle MC,
and are transferred to hair matrix KC, only during anagen [28, 35]. This would explain
why only anagen follicles come under attack, and why the incriminated autoantigenic
MRP-DP can be presented by both KC and MC, provided MHC I-molecules carry them
to the cell surface.
That MC-associated antigens can indeed be immunogenic autoantigens is demon-
strated by the cytotoxic autoantibodies against normal MC found in vitiligo [56-58], and
by the antibodies to unidentified melanoma antigens described in some AA patients [59].
Yet, the very large number ofgene products involved in melanogenesis and melanosome
construction [54, 55, 72] makes it difficult to narrow down the list of candidate MRP
serving as donors for MRP-DP.
The higher incidence of vitiligo in AA patients has been interpreted to suggest that
the same MC-derived antigens are autoimmune targets in both vitiligo and AA, and the
MC-related autoantibodies found in some AA patients [59], namely in those with both
AAand vitiligo, might help to identify the MRP-DP incriminated in AA.
However, there is currently no convincing immunnological evidence availabe that
AA and vitiligo share the same pathogenesis: on the contrary, both diseases are too rarely
associated (only 1-4% of AA patients have vitiligo [1] and autoantibodies in vitiligo
attest to a B cell-mediated autoimmune response; according to the immunological vitiligo
theories, acomplement-mediated, antibody-dependent cytotoxicity reaction may underlie
the development ofvitiligo [58, 73], but not the cell-mediated autoimmune-attack in AA
[1, 3, 36]. Also, the MRP-DP incriminated in AA may only begenerated in follicular, but
not epidermal MC. Together, this would explain why epidermal MC are not attacked in
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secondary immune response, which may give rise to the mentioned autoantibodies, AA
patients would also develop vitiligo. In short, the autoantibodies found in AA or vitiligo
probably are misleading guides for identifying the MRP-DP in question.
More pertinent clues arise from the finding thatcytolytic T cells can be isolated from
patients with certain MHC I expressing melanomas [60, 75]. Forexample, these cytolytic
T cells recognize and respond to an HLA-A2-presented antigen coded for by the tyrosi-
nase gene [60]. Enzymatically active tyrosinase, or protein products of alternatively
spliced tyrosinase mRNAs serving as "receptors/transporters" for L-tyrosine or L-DOPA
[61], would be present only during active melanogenesis (i.e., anagen III-VI), and, as in
melanoma, could be presented by MHC I-molecules. Therefore, we currently favor
tyrosinase gene products as sources for the incriminated MRP-DP, since their presenta-
tion by MHC I and recognition by autoreactive Tcells has been demonstrated conclusive-
ly [60]. We recognize that the new research focus suggested here (MHC I-presented
melanocyte-associated antigens recognized by CD8+ T cells) will quickly reveal addi-
tional candidate proteins [cf. 75].
In summary, though many circumstances and events predispose to developing AA,
none of them suffices to induce it, and the chance for all of them to coincide is indeed
small. While this explains the low incidence of AA, it also provides a rationale for the
frequent recurrence of AA attacks, since now the depicted chain of predisposing events
may be linked together more easily, for example due to the local presence of primed
autoreactive T cells and the persistance of a high level of MHC I expression in a given
skin area.
PERSPECTIVES
Since our hypothesis is quite specific, it can be put to the test. Crucial support would
arise from the demonstration that AA patients have CD8+ T cells responding to MHC I-
presented MRP-DP in vitro. Ifchallenge with MRP or MRP-DP (in an MHC I-presenta-
tion setting) triggers AA-like symptoms in the anagen follicles ofnormal test animals, or
ofanimals with a MHC-haplotype predisposing them to the development ofautoimmune
disease, this hypothesis would also be supported strongly. The same applies iftheadmin-
istration of IFN-y, TNF-a or IL-I to non-lesional skin in AA patients or - ethically more
acceptable - in an available rat model of AA [63], induces a more rapid onset of AA
lesions than seen spontaneously. If, however, AA-like hair loss can be induced in experi-
mental animals that selectively lack follicular MC, MRP, CD8+ T cells or MHC I
molecules, our hypothesis becomes untenable.
Targeting the secondary immune response in AA certainly remains a good approach
for limiting secondary follicle damage but, according to this hypothesis, it is insufficient
for preventing disease progression and recurrence. The synchronization ofall anagen fol-
licles in the perimeter of an acute AA lesion into telogen should prevent progression of
the lesion, because this would switch-off of MRP synthesis. Another approach would be
to restore the local signal milieu maintaining relative MHC I-"negativity." Local adminis-
tration of potent analogues of a-MSH [64], a putative MHC I-suppressor [47] is one
option, assuming that the suppression of MHC I expression would prevent CD8+ T cell
recognition ofMRP-DP, even if this should stimulate follicular melanogenesis. The topi-Pausetal.: Alopecia areata: autoi ity againstmelanogenesis-relatedproteins? 5SI
cal application ofdrugs, hormones, or cytokines that inhibit melanogenesis orantagonize
IL-1, TNF-a and/orIFN-yshould now be considered in AA management, provided these
agents do not simultaneously up-regulate MHC I expression. Recently reported liposome
preparations that target the hair follicle [65] are particularly promising for the topical
delivery of a-MSH agonists, MHC I-stimulators, melanogenesis-inhibitors, and/or IL-I-,
IFN-y- orTNF-a-antagonists.
Corticosteroids have established suppressive effects on inflammatory infiltrates and
on cytokine secretion [45] which makes them useful tools for suppressing the proposed
secondary attack in AA. In addition, they may switch-offfollicular melanogenesis: potent
topical corticosteroids suppress anagen development in mice, which entails the suppre-
sion offollicular melanogenesis [66]. However, that even potent corticosteroids are only
partially effective in AA and do not prevent its recurrence might reflect an inhibitory
effect ofthese drugs on the local generation ofa-MSH [48] so that MHC I expression is
not effectively downregulated. Also, corticosteroids are not appreciated as down-regula-
tors of MHC I expression. The unsatisfactory response of AA to immunomodulatory
treatment (incl. contact sensitizers, anthralin, cyclosporine A, corticosteroids, UV-irradia-
tion) that is characterized by ahigh relapse rate afterdiscontinuation oftherapy invites to
study how these agents modify the expression of MHC I and MRP-DP in the proximal
anagen hair bulb. This may provide clues as to why and when these agents work, so they
can beused more discriminatingly.
Several Tcell-directed management strategies [67] for AA follow logically from our
hypothesis. Besides the clinically rather unattractive, non-specific depletion of CD8+ T
cells by appropriate antibodies, the putative MRP-DP autoreactive CD8+ T cells may be
specifically "tolerized" by administering peptides that make a fit with the incriminated
MHC I molecules, but fail to activate the T cells. Even the induction oforal tolerance by
feeding of MRP-DP is a rational option, given the encouraging initial results obtained
with the oral administration of myelin basic protein in the prevention and treatment of
multiple sclerosis and of type II collagen in the management of rheumatoid arthritis
[67-69]. Priortoclinical studies, all these approaches can be tested in the DEBR ratmod-
el ofAA [63].
The AA literature documents the keen interest many dermatologists have long
kindled for this fascinating disease [1, 2, 36, 44], but it also shows that AA has not
enjoyed much attention from immunologists specializing in autoimmune diseases - most
textbooks on clinical immunology or autoimmunity do not even mention AA. This field
would greatly profit ifprofessional immunologists finally were to discover the intricacies
and surprises of hair follicle immunology in health and disease [21, 22, 30-32, 70, 71].
From a theoretical, experimental and clinical perspective, the study of AA is an ideal
point of entry for exploring the immunology of the hair follicle and the concept of
autoimmunity to normally sequestered, rhythmically generated, MHC I-dependent
antigens.
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